TY - JOUR AU - Bray, F. AU - Ferlay, J. AU - Soerjomataram, I. AU - Siegel, R. L. AU - Torre, L. A. AU - Jemal, A. PY - 2018 DA - 2018// TI - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin VL - 68 ID - Bray2018 ER - TY - JOUR AU - Chen, W. AU - Zheng, R. AU - Baade, P. D. AU - Zhang, S. AU - Zeng, H. AU - Bray, F. PY - 2016 DA - 2016// TI - Cancer statistics in China, 2015 JO - CA Cancer J Clin VL - 66 UR - https://doi.org/10.3322/caac.21338 DO - 10.3322/caac.21338 ID - Chen2016 ER - TY - JOUR AU - Bickenbach, K. AU - Strong, V. E. PY - 2012 DA - 2012// TI - Comparisons of gastric Cancer treatments: east vs JO - West J Gastric Cancer VL - 12 UR - https://doi.org/10.5230/jgc.2012.12.2.55 DO - 10.5230/jgc.2012.12.2.55 ID - Bickenbach2012 ER - TY - JOUR AU - Lui, F. H. AU - Tuan, B. AU - Swenson, S. L. AU - Wong, R. J. PY - 2014 DA - 2014// TI - Ethnic disparities in gastric cancer incidence and survival in the USA: an updated analysis of 1992-2009 SEER data JO - Dig Dis Sci VL - 59 UR - https://doi.org/10.1007/s10620-014-3275-3 DO - 10.1007/s10620-014-3275-3 ID - Lui2014 ER - TY - JOUR AU - Ye, X. S. AU - Yu, C. AU - Aggarwal, A. AU - Reinhard, C. PY - 2016 DA - 2016// TI - Genomic alterations and molecular subtypes of gastric cancers in Asians JO - Chin J Cancer VL - 35 UR - https://doi.org/10.1186/s40880-016-0106-2 DO - 10.1186/s40880-016-0106-2 ID - Ye2016 ER - TY - JOUR AU - Cutsem, E. AU - Moiseyenko, V. M. AU - Tjulandin, S. AU - Majlis, A. AU - Constenla, M. AU - Boni, C. PY - 2006 DA - 2006// TI - Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.06.8429 DO - 10.1200/JCO.2006.06.8429 ID - Cutsem2006 ER - TY - JOUR AU - Shah, M. A. AU - Janjigian, Y. Y. AU - Stoller, R. AU - Shibata, S. AU - Kemeny, M. AU - Krishnamurthi, S. PY - 2015 DA - 2015// TI - Randomized multicenter phase II study of modified Docetaxel, Cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric Cancer consortium JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.60.7465 DO - 10.1200/JCO.2015.60.7465 ID - Shah2015 ER - TY - JOUR AU - Al-Batran, S. E. AU - Hartmann, J. T. AU - Probst, S. AU - Schmalenberg, H. AU - Hollerbach, S. AU - Hofheinz, R. PY - 2008 DA - 2008// TI - Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.9378 DO - 10.1200/JCO.2007.13.9378 ID - Al-Batran2008 ER - TY - JOUR AU - Kang, Y. K. AU - Kang, W. K. AU - Shin, D. B. AU - Chen, J. AU - Xiong, J. AU - Wang, J. PY - 2009 DA - 2009// TI - Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial JO - Ann Oncol VL - 20 UR - https://doi.org/10.1093/annonc/mdn717 DO - 10.1093/annonc/mdn717 ID - Kang2009 ER - TY - JOUR AU - Bang, Y. J. AU - Cutsem, E. AU - Feyereislova, A. AU - Chung, H. C. AU - Shen, L. AU - Sawaki, A. PY - 2010 DA - 2010// TI - Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial JO - Lancet. VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)61121-X DO - 10.1016/S0140-6736(10)61121-X ID - Bang2010 ER - TY - JOUR AU - Wei, S. C. AU - Duffy, C. R. AU - Allison, J. P. PY - 2018 DA - 2018// TI - Fundamental mechanisms of immune checkpoint blockade therapy JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0367 DO - 10.1158/2159-8290.CD-18-0367 ID - Wei2018 ER - TY - JOUR AU - Park, Y. J. AU - Kuen, D. S. AU - Chung, Y. PY - 2018 DA - 2018// TI - Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance JO - Exp Mol Med VL - 50 UR - https://doi.org/10.1038/s12276-018-0130-1 DO - 10.1038/s12276-018-0130-1 ID - Park2018 ER - TY - JOUR AU - Marin-Acevedo, J. A. AU - Dholaria, B. AU - Soyano, A. E. AU - Knutson, K. L. AU - Chumsri, S. AU - Lou, Y. PY - 2018 DA - 2018// TI - Next generation of immune checkpoint therapy in cancer: new developments and challenges JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0582-8 DO - 10.1186/s13045-018-0582-8 ID - Marin-Acevedo2018 ER - TY - STD TI - Lowther DE, Goods BA, Lucca LE, Lerner BA, Raddassi K, van Dijk D, et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight. 2016;1(5):e85935. ID - ref14 ER - TY - JOUR AU - Dong, H. AU - Strome, S. E. AU - Salomao, D. R. AU - Tamura, H. AU - Hirano, F. AU - Flies, D. B. PY - 2002 DA - 2002// TI - Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion JO - Nat Med VL - 8 UR - https://doi.org/10.1038/nm730 DO - 10.1038/nm730 ID - Dong2002 ER - TY - JOUR AU - Muro, K. AU - Chung, H. C. AU - Shankaran, V. AU - Geva, R. AU - Catenacci, D. AU - Gupta, S. PY - 2016 DA - 2016// TI - Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)00175-3 DO - 10.1016/S1470-2045(16)00175-3 ID - Muro2016 ER - TY - JOUR AU - Fuchs, C. S. AU - Doi, T. AU - Jang, R. W. AU - Muro, K. AU - Satoh, T. AU - Machado, M. PY - 2018 DA - 2018// TI - Safety and efficacy of Pembrolizumab Monotherapy in patients with previously treated advanced gastric and Gastroesophageal junction Cancer: phase 2 clinical KEYNOTE-059 trial JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.0013 DO - 10.1001/jamaoncol.2018.0013 ID - Fuchs2018 ER - TY - JOUR AU - Kang, Y. K. AU - Boku, N. AU - Satoh, T. AU - Ryu, M. H. AU - Chao, Y. AU - Kato, K. PY - 2017 DA - 2017// TI - Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet. VL - 390 UR - https://doi.org/10.1016/S0140-6736(17)31827-5 DO - 10.1016/S0140-6736(17)31827-5 ID - Kang2017 ER - TY - JOUR AU - Song, M. AU - Chen, X. AU - Wang, L. AU - Zhang, Y. PY - 2018 DA - 2018// TI - Future of anti-PD-1/PD-L1 applications: combinations with other therapeutic regimens JO - Chin J Cancer Res VL - 30 UR - https://doi.org/10.21147/j.issn.1000-9604.2018.02.01 DO - 10.21147/j.issn.1000-9604.2018.02.01 ID - Song2018 ER - TY - JOUR AU - Gandhi, L. AU - Rodriguez-Abreu, D. AU - Gadgeel, S. AU - Esteban, E. AU - Felip, E. AU - Angelis, F. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1801005 DO - 10.1056/NEJMoa1801005 ID - Gandhi2018 ER - TY - JOUR AU - Paz-Ares, L. AU - Luft, A. AU - Vicente, D. AU - Tafreshi, A. AU - Gumus, M. AU - Mazieres, J. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy for squamous non-small-cell lung Cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1810865 DO - 10.1056/NEJMoa1810865 ID - Paz-Ares2018 ER - TY - JOUR AU - Yan, Y. AU - Kumar, A. B. AU - Finnes, H. AU - Markovic, S. N. AU - Park, S. AU - Dronca, R. S. PY - 2018 DA - 2018// TI - Combining immune checkpoint inhibitors with conventional Cancer therapy JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.01739 DO - 10.3389/fimmu.2018.01739 ID - Yan2018 ER - TY - JOUR AU - Wang, J. AU - Fei, K. AU - Jing, H. AU - Wu, Z. AU - Wu, W. AU - Zhou, S. PY - 2019 DA - 2019// TI - Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit JO - MAbs. VL - 11 UR - https://doi.org/10.1080/19420862.2019.1654303 DO - 10.1080/19420862.2019.1654303 ID - Wang2019 ER - TY - BOOK AU - Brierley, J. D. AU - Gospodarowicz, M. K. AU - Wittekind, C. PY - 2017 DA - 2017// TI - TNM classification of malignant tumours PB - Wiley CY - Oxford ID - Brierley2017 ER - TY - BOOK PY - 2019 DA - 2019// TI - Guidelines for Gastric Cancer. Version 2 ID - ref25 ER - TY - JOUR AU - Cunningham, D. AU - Starling, N. AU - Rao, S. AU - Iveson, T. AU - Nicolson, M. AU - Coxon, F. PY - 2008 DA - 2008// TI - Capecitabine and oxaliplatin for advanced esophagogastric cancer JO - N Engl J Med VL - 358 UR - https://doi.org/10.1056/NEJMoa073149 DO - 10.1056/NEJMoa073149 ID - Cunningham2008 ER - TY - JOUR AU - Lordick, F. AU - Kang, Y. K. AU - Chung, H. C. AU - Salman, P. AU - Oh, S. C. AU - Bodoky, G. PY - 2013 DA - 2013// TI - Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial JO - Lancet Oncol. VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70102-5 DO - 10.1016/S1470-2045(13)70102-5 ID - Lordick2013 ER - TY - JOUR AU - Waddell, T. AU - Chau, I. AU - Cunningham, D. AU - Gonzalez, D. AU - Okines, A. F. AU - Okines, C. PY - 2013 DA - 2013// TI - Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial JO - Lancet Oncol. VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70096-2 DO - 10.1016/S1470-2045(13)70096-2 ID - Waddell2013 ER - TY - JOUR AU - Bang, Y. J. AU - Kang, Y. K. AU - Catenacci, D. V. AU - Muro, K. AU - Fuchs, C. S. AU - Geva, R. PY - 2019 DA - 2019// TI - Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study JO - Gastric Cancer VL - 22 UR - https://doi.org/10.1007/s10120-018-00909-5 DO - 10.1007/s10120-018-00909-5 ID - Bang2019 ER - TY - JOUR AU - Boku, N. AU - Ryu, M. H. AU - Kato, K. AU - Chung, H. C. AU - Minashi, K. AU - Lee, K. W. PY - 2019 DA - 2019// TI - Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdy540 DO - 10.1093/annonc/mdy540 ID - Boku2019 ER - TY - STD TI - Tabernero J, Cutsem EV, Bang YJ, Fuchs CS, Wyrwicz L, Lee K-W, et al. Pembrolizumab with or without chemotherapy versus chemotherapy in advanced G/GEJ adenocarcinoma the phase 3, keynote-062 study. J Clin Oncol. 2019;37(18):suppl.LBA4007. ID - ref31 ER - TY - STD TI - Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30(9):1479–86. ID - ref32 ER - TY - JOUR AU - Cai, H. AU - Jing, C. AU - Chang, X. AU - Ding, D. AU - Han, T. AU - Yang, J. PY - 2019 DA - 2019// TI - Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing JO - J Transl Med VL - 17 UR - https://doi.org/10.1186/s12967-019-1941-0 DO - 10.1186/s12967-019-1941-0 ID - Cai2019 ER - TY - JOUR AU - Mishima, S. AU - Kawazoe, A. AU - Nakamura, Y. AU - Sasaki, A. AU - Kotani, D. AU - Kuboki, Y. PY - 2019 DA - 2019// TI - Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0514-3 DO - 10.1186/s40425-019-0514-3 ID - Mishima2019 ER -